On Simon's two-stage design for single-arm phase IIA cancer clinical trials under beta-binomial distribution
- PMID: 20077506
- DOI: 10.1002/sim.3805
On Simon's two-stage design for single-arm phase IIA cancer clinical trials under beta-binomial distribution
Abstract
Simon (Control. Clin. Trials 1989; 10:1-10)'s two-stage design has been broadly applied to single-arm phase IIA cancer clinical trials in order to minimize either the expected or the maximum sample size under the null hypothesis of drug inefficacy, i.e. when the pre-specified amount of improvement in response rate (RR) is not expected to be observed. This paper studies a realistic scenario where the standard and experimental treatment RRs follow two continuous distributions (e.g. beta distribution) rather than two single values. The binomial probabilities in Simon's (Control. Clin. Trials 1989; 10:1-10) design are replaced by prior predictive Beta-binomial probabilities that are the ratios of two beta functions and domain-restricted RRs involve incomplete beta functions to induce the null hypothesis acceptance probability. We illustrate that Beta-binomial mixture model based two-stage design retains certain desirable properties for hypothesis testing purpose. However, numerical results show that such designs may not exist under certain hypothesis and error rate (type I and II) setups within maximal sample size approximately 130. Furthermore, we give theoretical conditions for asymptotic two-stage design non-existence (sample size goes to infinity) in order to improve the efficiency of design search and to avoid needless searching.
Similar articles
-
Interval estimation of binomial proportion in clinical trials with a two-stage design.Stat Med. 2008 Jan 15;27(1):15-35. doi: 10.1002/sim.2930. Stat Med. 2008. PMID: 17566141
-
Optimal and minimax three-stage designs for phase II oncology clinical trials.Contemp Clin Trials. 2008 Jan;29(1):32-41. doi: 10.1016/j.cct.2007.04.008. Epub 2007 May 6. Contemp Clin Trials. 2008. PMID: 17544337
-
Adaptive two-stage designs in phase II clinical trials.Stat Med. 2006 Oct 15;25(19):3382-95. doi: 10.1002/sim.2501. Stat Med. 2006. PMID: 16479547
-
Randomized phase II designs in cancer clinical trials: current status and future directions.J Clin Oncol. 2005 Jul 1;23(19):4450-7. doi: 10.1200/JCO.2005.03.197. J Clin Oncol. 2005. PMID: 15994154 Review.
-
On design considerations and randomization-based inference for community intervention trials.Stat Med. 1996 Jun 15;15(11):1069-92. doi: 10.1002/(SICI)1097-0258(19960615)15:11<1069::AID-SIM220>3.0.CO;2-Q. Stat Med. 1996. PMID: 8804140 Review.
Cited by
-
Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial.Transl Cancer Res. 2019 Jul;8(Suppl 4):S404-S420. doi: 10.21037/tcr.2019.05.17. Transl Cancer Res. 2019. PMID: 31456910 Free PMC article.
-
The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials.Pharm Stat. 2021 Nov;20(6):1183-1199. doi: 10.1002/pst.2139. Epub 2021 May 19. Pharm Stat. 2021. PMID: 34008317 Free PMC article. Clinical Trial.
-
A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.Eur J Cancer Care (Engl). 2013 Sep;22(5):605-11. doi: 10.1111/ecc.12065. Epub 2013 May 23. Eur J Cancer Care (Engl). 2013. PMID: 23701251 Free PMC article. Clinical Trial.